Paul Matteis

Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug

Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In Dementia

Stifel Bullish On GW Pharma, Sees $1.5 Billion In Epidiolex Sales By 2023

Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In Dementia

Stifel Bullish On GW Pharma, Sees $1.5 Billion In Epidiolex Sales By 2023

Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate

4 Reasons Behind Stifel's Neurocrine Bull Thesis

Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate

4 Reasons Behind Stifel's Neurocrine Bull Thesis

Alder An Attractive Play In Migraine Market, Stifel Says Ahead Of Quarterly Report

Why Leerink Adjusted Upside Expectations For 3 Biotechs